drugset / Trial / NCT04931342
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
Phase 2
Active not recruiting
176 enrolled
Hoffmann-La Roche
European Network of Gynaecological Oncological Trial Groups (ENGOT) · collabGOG Foundation · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy and safety of multiple biomarker-selected treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumors. Enrollment will take place in two phases: a preliminary phase followed by a potential expansion phase.
Timeline
- Start
- 2021-10-07
- Primary completion
- 2028-02-28
- Completion
- 2028-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | — | Oral |
| Subject | Atezolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Cobimetinib | Small molecule | — | Oral |
| Subject | Cyclophosphamide | Other / unclassified | — | Oral |
| Subject | Giredestrant | Small molecule | — | Oral |
| Subject | Inavolisib | Small molecule | — | Oral |
| Subject | Ipatasertib | Small molecule | — | Oral |
| Subject | Letrozole | Other / unclassified | — | Oral |
| Subject | Olaparib | Small molecule | — | Oral |
| Subject | Paclitaxel | Small molecule | — | Intravenous |
| Subject | Palbociclib | Small molecule | — | Oral |
| Subject | Trastuzumab emtansine | Other / unclassified | — | Intravenous |
| Background | Goserelin | Other / unclassified | — | — |
| Background | Leuprolide | Other / unclassified | — | — |
| Background | Triptorelin | Other / unclassified | — | — |